FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person * GERSON IRWIN				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/23/2007						Office	r (give title belo	ow)	Other (specify	pelow)	
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date any (Month/Day/Ye	, if ((Instr. 8)		1		of (D)	Beneficia	ant of Securities fally Owned Following d Transaction(s)		Ownership Form:	7. Nature of Indirect Beneficial Ownership	
				(Monui/Day/ 1 e	ai)	Code	V	Amoun	(A) or (D)	Price		. 3 and +)		or Indirect (I) (Instr. 4)	(Instr. 4)
Restricted Stock Units (1) 01/23/2007					A	7,000 A (1)		57,190 ⁽²⁾			D				
				Derivative Secui		Acquire	conta the fo	ained ir orm dis sposed o	this for plays a f, or Ben	rm ar curre reficia	e not requently valid		ormation spond unle trol numbe	ss	1474 (9-02)
1. Title of	2.	3. Transaction	1	4.	5.	ints, opt		ate Exerc			itle and	8. Price of	9. Number	of 10.	11. Natur
Security	Conversion or Exercise Price of Derivative Security		Year) any	tte, if Transactic Code Year) (Instr. 8)	of Dec Sec Acc (A) Dis of (Inc.)			and Expiration Date (Month/Day/Year)		Uno Sec	Amount of Juderlying Securities Instr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	Ownersh (Instr. 4) D) ect
				Code V	7 (A		Date Exerc		Expiratio Date	n Titl	Amount or e Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
GERSON IRWIN C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X					

Signatures

/s/ Irwin C. Gerson	01/23/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On January 23, 2007, the Reporting Person was granted 7,000 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted (1) Stock Unit consists of a right to the issuance of one share of common stock, par value \$.01 ("Common Stock"). The Restricted Stock Units are subject to a two-year vesting period.
- (2) As of the date hereof, the Reporting Person has a direct beneficial ownership interest in: (a) 2,500 shares of Common Stock; and (b) stock options to purchase 54,690 shares of Common Stock. The Reporting Person also owns 9,500 Restricted Stock Units that will not vest within the next 60 days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.